Document Classification

Section Type: RESULTS

Text: Patients receiving active vitamin treatment had similar risk for the composite CVD primary end point (226. 9 / 10, 000 person-years vs 219. 2 / 10, 000 person-years for the active vs placebo group ; relative risk [RR], 1. 03 ; 95 % confidence interval [CI], 0. 90-1. 19 ; P =. 65), as well as for the secondary outcomes including myocardial infarction (34. 5 / 10, 000 person-years vs 39. 5 / 10, 000 person-years ; RR, 0. 87 ; 95 % CI, 0. 63-1. 22 ; P =. 42), stroke (41. 9 / 10, 000 person-years vs 36. 8 / 10, 000 person-years ; RR, 1. 14 ; 95 % CI, 0. 82-1. 57 ; P =. 44), and CVD mortality (50. 3 / 10, 000 person-years vs 49. 6 / 10, 000 person-years ; RR, 1. 01 ; 95 % CI, 0. 76-1. 35 ; P =. 93).